Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

VGLL-fused intraparenchymal schwannoma with EWSR1::VGLL1 fusion: integrated clinicopathological and molecular characterization.

Acta neuropathologica communications·2026
Same author

Central Nervous System Embryonal Tumour With PLAGL Amplification Lacking Typical Embryonal Morphology: Diagnostic Pitfall in a Paediatric Case.

Neuropathology and applied neurobiology·2026
Same author

Possible involvement of genome-wide near-haploidy and <i>MEN1</i> mutation in the molecular pathogenesis of pituitary carcinoma: Analysis by whole exome sequencing.

Neuro-oncology advances·2026
Same author

A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART).

Japanese journal of clinical oncology·2026
Same author

Secondary atypical teratoid/rhabdoid tumors are not necessarily categorized as AT/RT by DNA methylation analysis.

Journal of neuropathology and experimental neurology·2026
Same author

Epstein-Barr virus-associated smooth muscle tumor of the liver after umbilical cord blood transplantation for acute myeloid leukemia.

Clinical journal of gastroenterology·2026

Related Experiment Video

Updated: May 26, 2026

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

[IDH1/2 mutations in gliomas].

Sumihito Nobusawa1, Hideaki Yokoo

  • 1Department of Human Pathology, Gunma University Graduate School of Medicine, Gunma, Japan.

Brain and Nerve = Shinkei Kenkyu No Shinpo
|December 8, 2011
PubMed
Summary

Mutations in isocitrate dehydrogenases 1 and 2 (IDH1/2) are common in gliomas. Their impact on high-grade gliomas is known, but their prognostic significance in low-grade gliomas requires further investigation.

Area of Science:

  • Biochemistry
  • Oncology
  • Neuroscience

Background:

  • Isocitrate dehydrogenases 1 and 2 (IDH1/2) are key enzymes in cellular metabolism.
  • IDH1/2 mutations are prevalent in various glioma subtypes, including low-grade and high-grade gliomas.
  • These mutations are specific to single codons, making them attractive biomarkers.

Purpose of the Study:

  • To investigate the clinical impact of IDH1/2 mutations on glioma patients.
  • To clarify the prognostic significance of IDH1/2 mutations, particularly in low-grade diffuse gliomas.
  • To explore the role of IDH1/2 mutations in gliomagenesis for potential therapeutic strategies.

Main Methods:

  • Review of existing studies on IDH1/2 mutations in gliomas.
  • Analysis of clinical data correlating IDH1/2 mutation status with glioma grade and patient outcomes.

More Related Videos

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

Related Experiment Videos

Last Updated: May 26, 2026

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

  • Biochemical and molecular pathway analysis to understand the role of IDH1/2 in gliomagenesis.

    • Main Results:

    • IDH1/2 mutations have a well-established favorable prognostic influence in high-grade gliomas.
    • The prognostic impact of IDH1/2 mutations in low-grade diffuse gliomas remains less clear and requires further research.
    • The precise mechanism by which IDH1/2 mutations contribute to glioma development is still under investigation.

    Conclusions:

    • IDH1/2 mutations are significant in glioma biology, with differential prognostic implications across tumor grades.
    • Further research is needed to fully understand the prognostic value of IDH1/2 mutations in low-grade gliomas.
    • Elucidating the role of IDH1/2 mutations in gliomagenesis may unlock new therapeutic avenues for glioma treatment.